August 2021

The immune biology of the neuroblastoma microenvironment is an emerging field.

The future is rapidly approaching; several hundred trials are using circulating tumor DNA detection and quantification for either intervention or observation.

The benefit of using a drug off-label is that it may provide the best available intervention for a patient with no other option.

Rising interest in SSTR2-targeted radiopharmaceuticals has led to the evaluation of numerous ways to optimize peptide receptor radionuclide therapy in patients with neuroendocrine tumors.

Adding the targeted radioligand LuPSMA to standard of care therapy for patients with metastatic castration resistant prostate cancer after androgen receptor pathway inhibition and chemotherapy extended overall survival and delayed disease progression

Nanotechnology advances in oncology have applications in diagnosis, biomarker screening, and most notably, treatment.

As more chimeric antigen receptors undergo clinical development for the treatment of hematologic malignancies, their approval for use in a wider array of malignancies is inevitable.

Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.